TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26182832

Group type: EXPERIMENTAL
Intervention: CXCR2 antagonist AZD5069 (100 mg), twice daily orally for 6 days
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: CXCR2 antagonist AZD5069 (100 mg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Subcutaneous G‐CSF on day 5
Number of subjects: 30
Study: 25660414

Group type: EXPERIMENTAL
Intervention: Amino acid supplementation twice daily
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo supplementation twice daily
Number of subjects: 14
Study: 24377096

Group type: EXPERIMENTAL
Intervention: Kinesiology Taping (KT), n = 20
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Quasi Kinesiology Taping (Quasi KT), n = 22
Number of subjects: 65

Group type: COMPARATOR
Intervention: Multilayered Compression Therapy (MCT), n = 23
Number of subjects: 65
Study: 20190243

Group type: EXPERIMENTAL
Intervention: Intradialytic exercise training (cycling)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Non-exercising control group
Number of subjects: 17
Study: 18684664

Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT)
Number of subjects: 813

Group type: COMPARATOR
Intervention: Optimal pharmacological treatment
Number of subjects: 813
Study: 16634845

Group type: EXPERIMENTAL
Intervention: Intoxicated high HR responders
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Intoxicated low HR responders
Number of subjects: 147

Group type: COMPARATOR
Intervention: Sober controls
Number of subjects: 147
Study: 12816824

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (0.05% cream or 0.005% ointment) applied twice weekly
Number of subjects: 295

Group type: COMPARATOR
Intervention: Emollient alone (placebo) applied twice weekly
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate cream applied twice weekly
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate ointment applied twice weekly
Number of subjects: 295
Study: 11189684

Group type: EXPERIMENTAL
Intervention: Screening with flexible sigmoidoscopy (60‐cm sigmoidoscope)
Number of subjects: 74000

Group type: EXPERIMENTAL
Intervention: Screening with chest X‐ray
Number of subjects: 74000

Group type: EXPERIMENTAL
Intervention: Screening men with digital rectal examination (DRE) plus serum prostate‐specific antigen (PSA)
Number of subjects: 74000

Group type: EXPERIMENTAL
Intervention: Screening women with CA125 and transvaginal ultrasound (TVU)
Number of subjects: 74000

Group type: COMPARATOR
Intervention: Usual medical care practices
Number of subjects: 74000
Study: 9254261

Group type: EXPERIMENTAL
Intervention: Intravenous perftoran infusion in 10-15 ml/kg dose
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (no perftoran infusion)
Number of subjects: 44
Study: 7963413

Group type: EXPERIMENTAL
Intervention: Indeterminate recombinant immunoblot assay 3.0 patterns
Number of subjects: 89
Study: 3297907

Group type: EXPERIMENTAL
Intervention: Paracentesis (4-6 L/day until disappearance of ascites) and intravenous albumin infusion (40 g after each tap)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Diuretics (spironolactone 200-400 mg/day plus furosemide 40-240 mg/day)
Number of subjects: 117
Study: 29120968

Group type: EXPERIMENTAL
Intervention: Pulmonary Rehabilitation (PR)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Calisthenics Training (CT)
Number of subjects: 30
Study: 29231409

Group type: EXPERIMENTAL
Intervention: Acupoint injection of salmon calcitonin (100 U, 4 mL total, 1 mL per acupoint)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Intramuscular injection of salmon calcitonin (100 U)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Blank group (0.9% sodium chloride injection, 1 mL per acupoint)
Number of subjects: 90
Study: 24751286

Group type: EXPERIMENTAL
Intervention: Continuous endotracheal tube cuff pressure control system
Number of subjects: 284

Group type: COMPARATOR
Intervention: Intermittent endotracheal tube cuff pressure control system
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: Endotracheal tube with lumen for subglottic secretion drainage (SSD)
Number of subjects: 284

Group type: COMPARATOR
Intervention: Endotracheal tube without lumen for SSD
Number of subjects: 284
Study: 21917326

Group type: EXPERIMENTAL
Intervention: Rhythm Control (RhyC)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Rate Control (RaC)
Number of subjects: 59
Study: 19837518

Group type: EXPERIMENTAL
Intervention: 50mg naltrexone
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Naltrexone + smoking a single cigarette
Number of subjects: 38
Study: 17535505

Group type: EXPERIMENTAL
Intervention: Cognitive appraisals (tolerance)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Cognitive appraisals (interference)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Visual acuity (symptom severity)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Cognitive appraisals (tolerance and interference)
Number of subjects: 113
Study: 16868803

Group type: EXPERIMENTAL
Intervention: Omeprazole 10 mg once daily
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg once daily
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Omeprazole 10 mg or 20 mg
Number of subjects: 37
Study: 12636954

Group type: EXPERIMENTAL
Intervention: Peer counseling intervention
Number of subjects: 142

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 142

Group type: COMPARATOR
Intervention: Smoking 1-6 cigarettes/day
Number of subjects: 142

Group type: COMPARATOR
Intervention: Smoking more than 6 cigarettes/day
Number of subjects: 142
Study: 10868015

Group type: EXPERIMENTAL
Intervention: Isokinetic strength training (4 weeks duration)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (regular physiotherapy only)
Number of subjects: 38
Study: 8865926

Group type: EXPERIMENTAL
Intervention: 1.1% amino acid dialysate (Nutrineal)
Number of subjects: 18
Study: 7898097

Group type: EXPERIMENTAL
Intervention: Cilazapril (2.5-5.0 mg once daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cilazapril
Number of subjects: 0
Study: 3301458

Group type: EXPERIMENTAL
Intervention: Naproxen sodium (550 mg initially, 275 mg every 6 h thereafter)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Pirprofen (400 mg every 8 h until pain relief or 3-day trial end)
Number of subjects: 100
Study: 30522497

Group type: EXPERIMENTAL
Intervention: Remotely supervised transcranial direct current stimulation (RS-tDCS) paired with cognitive training (CT) (2.0 mA × 20 min)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Remotely supervised transcranial direct current stimulation (RS-tDCS) paired with cognitive training (CT)
Number of subjects: 16
Study: 27296366

Group type: EXPERIMENTAL
Intervention: Group-based outpatient physiotherapy intervention (1-hour class weekly for 6 weeks)
Number of subjects: 256

Group type: COMPARATOR
Intervention: Usual care (booklet about exercise and referral for physiotherapy if deemed appropriate)
Number of subjects: 256
Study: 24695888

Group type: EXPERIMENTAL
Intervention: Food aromas in normal-weight subjects
Number of subjects: 48

Group type: COMPARATOR
Intervention: Food aromas in obese subjects
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Responses to food aromas in obese subjects
Number of subjects: 48
Study: 22738941

Group type: EXPERIMENTAL
Intervention: 3-week double-J stent placement
Number of subjects: 365

Group type: COMPARATOR
Intervention: 6-week double-J stent placement
Number of subjects: 365
Study: 19732856

Group type: EXPERIMENTAL
Intervention: Resistive vibration exercise (RVE) 11 times per week
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (bed rest only)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Resistive vibration exercise (RVE)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study: 18703875

Group type: EXPERIMENTAL
Intervention: Evidence-based algorithm treatment
Number of subjects: 63

Group type: COMPARATOR
Intervention: Individualised symptom-oriented treatment
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Algorithm treatment
Number of subjects: 63
Study: 16462914

Group type: EXPERIMENTAL
Intervention: Rofecoxib (50 mg, daily)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Tramadol (50 mg, 3 times per day)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (orally for 3 days)
Number of subjects: 15
Study: 12792208

Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging (MRI)
Number of subjects: 16
Study: 10872103

Group type: EXPERIMENTAL
Intervention: Generic pentoxifylline sustained-release (SR) tablet
Number of subjects: 12

Group type: COMPARATOR
Intervention: Trental 400
Number of subjects: 12
Study: 8803512

Group type: EXPERIMENTAL
Intervention: Glutamine (Group G)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Placebo (Group P)
Number of subjects: 151
Study: 1815531

Group type: EXPERIMENTAL
Intervention: Doxycyclin-Kapseln (test preparation)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Reference preparation (R)
Number of subjects: 20
Study: 6871470

Group type: EXPERIMENTAL
Intervention: random single-donor platelets (SD group)
Number of subjects: 54

Group type: COMPARATOR
Intervention: random multiple-donor platelet concentrates (MD group)
Number of subjects: 54
Study: 31045419

Group type: EXPERIMENTAL
Intervention: PROMIS® Depression scale
Number of subjects: 158

Group type: COMPARATOR
Intervention: Beck Depression Inventory (BDI‐II)
Number of subjects: 158
Study: 30071449

Group type: EXPERIMENTAL
Intervention: Micro-savings program with financial literacy training
Number of subjects: 1400

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 1400
Study: 26727241

Group type: EXPERIMENTAL
Intervention: Self-efficacy enhancement arm with self-weighing using Carematix scale, instructed to weigh at least 3 days per week or every other day.
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Self-efficacy enhancement arm with self-weighing
Number of subjects: 55
Study: 25026096

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 22753128

Group type: EXPERIMENTAL
Intervention: Experiential self-focus writing
Number of subjects: 182

Group type: COMPARATOR
Intervention: Control writing condition
Number of subjects: 182
Study: 19240374

Group type: EXPERIMENTAL
Intervention: High dose Th221 (60 mg/day)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Low dose Th221 (20.4 mg/day)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 17960962

Group type: EXPERIMENTAL
Intervention: Asenapine 5 mg b.i.d.
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Risperidone 3 mg b.i.d.
Number of subjects: 174

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 174
Study: 15909856

Group type: COMPARATOR
Intervention: Regimen I (standard high dose regimen) - 100 ml ASV loading dose followed by 50 ml every six hours
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Regimen II - 30 ml ASV loading dose followed by 30 ml continuous infusion every six hours
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Regimen III - 70 ml ASV loading dose followed by 30 ml continuous infusion every six hours
Number of subjects: 90
Study: 12466688

Group type: EXPERIMENTAL
Intervention: Therapeutic tape
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo tape
Number of subjects: 22

Group type: COMPARATOR
Intervention: No tape
Number of subjects: 22
Study: 9585823

Group type: EXPERIMENTAL
Intervention: OM-85-BV (3.5 mg of bacterial extracts)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 8581845

Group type: EXPERIMENTAL
Intervention: Prednisolone
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 2632749

Group type: EXPERIMENTAL
Intervention: 30 mg hydrocortisone (20 + 10 mg versus 10 + 20 mg, a.m./p.m.)
Number of subjects: 0
Study: 319006

Group type: EXPERIMENTAL
Intervention: Atenolol 3 mg intravenous
Number of subjects: 10

Group type: COMPARATOR
Intervention: Salbutamol (ordinary therapeutic dose by inhalation)
Number of subjects: 10
Study: 29974808

Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy
Number of subjects: 120

Group type: COMPARATOR
Intervention: Selective serotonin reuptake inhibitor
Number of subjects: 120

Group type: COMPARATOR
Intervention: Psycho-education
Number of subjects: 120
Study: 31877163

Group type: EXPERIMENTAL
Intervention: Life Skills Education program
Number of subjects: 271

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 271
Study: 28408711

Group type: EXPERIMENTAL
Intervention: Commencing PD at 1 week (G1)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Commencing PD at 2 weeks (G2)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Commencing PD at 4 weeks (G3)
Number of subjects: 122
Study: 26162609

Group type: EXPERIMENTAL
Intervention: Neoadjuvant CAPOX followed by chemoradiotherapy, surgery and adjuvant CAPOX plus cetuximab
Number of subjects: 155

Group type: COMPARATOR
Intervention: Neoadjuvant CAPOX followed by chemoradiotherapy, surgery and adjuvant CAPOX without cetuximab
Number of subjects: 155

Group type: COMPARATOR
Intervention: Neoadjuvant CAPOX followed by chemoradiotherapy, surgery and adjuvant CAPOX with cetuximab
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: LCS-6 TT genotype
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: LCS-6 TG genotype
Number of subjects: 155
Study: 23791153

Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol (800 μg)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study: 21334499

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Relaxation Therapy
Number of subjects: 105

Group type: COMPARATOR
Intervention: Usual Medical Care
Number of subjects: 105
Study: 18071022

Group type: EXPERIMENTAL
Intervention: Leicester Cough Questionnaire (LCQ)
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Cough Quality of Life Questionnaire (CQLQ)
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: CQLQ
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Generic health status measure (EuroQol)
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: CQLQ and LCQ correlation
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: EuroQol visual analog scale
Number of subjects: 147
Study: 16788683

Group type: EXPERIMENTAL
Intervention: COBAS Amplicor CMV Monitor (CACM)
Number of subjects: 72

Group type: COMPARATOR
Intervention: In-house PCR assay
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Patients developing HCMV disease
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Seropositive patients receiving a seronegative graft
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: HCMV infection
Number of subjects: 72
Study: 15648589

Group type: EXPERIMENTAL
Intervention: Hydrocolloid application
Number of subjects: 0

Group type: COMPARATOR
Intervention: Guideline application
Number of subjects: 0
Study: 11084571

Group type: EXPERIMENTAL
Intervention: Complex cysts (characteristics: septum, solid component, irregular or thick wall)
Number of subjects: 20000

Group type: EXPERIMENTAL
Intervention: Long-term oral contraceptive use
Number of subjects: 20000

Group type: EXPERIMENTAL
Intervention: Family history of ovarian cancer or multiple breast cancers
Number of subjects: 20000

Group type: EXPERIMENTAL
Intervention: Other abnormalities (including simple cysts, bilateral cysts, or all abnormalities combined)
Number of subjects: 20000
Study: 9260370

Group type: EXPERIMENTAL
Intervention: Hyperfractionated radiotherapy (HFT) - 81.6 Gy/68 fractions in 7 weeks
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Concomitant boost radiotherapy (CBT) - 72.3 Gy/42 fractions in 6 weeks
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: HFT
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: CBT
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: HFT and CBT
Number of subjects: 68
Study: 7691013

Group type: EXPERIMENTAL
Intervention: Flexible cystoscopy
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Rigid cystoscopy
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control group (no cystoscopy)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Prostate biopsy
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: TURP
Number of subjects: 101
Study: 3575603

Group type: EXPERIMENTAL
Intervention: Isoproterenol
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 12
Study: 30144429

Group type: EXPERIMENTAL
Intervention: Obeticholic Acid (OCA) 5, 10, or 25 mg/d for 17 days
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Obeticholic Acid (OCA) 10 mg/kg for 2 weeks in mice
Number of subjects: 24

Group type: COMPARATOR
Intervention: Water or vehicle (control) in mice
Number of subjects: 24
Study: 26563519

Group type: EXPERIMENTAL
Intervention: Topical recombinant human epidermal growth factor (EGF) cream
Number of subjects: 80

Group type: COMPARATOR
Intervention: Vehicle without EGF
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Four additional therapeutic moisturizers
Number of subjects: 80
Study: 24912060

Group type: EXPERIMENTAL
Intervention: Supported Employment
Number of subjects: 64

Group type: COMPARATOR
Intervention: Standard Vocational Rehabilitation Services
Number of subjects: 64

Group type: COMPARATOR
Intervention: Psychosocial Clubhouse Program
Number of subjects: 64
Study: 22284328

Group type: EXPERIMENTAL
Intervention: Cre8 stents
Number of subjects: 323

Group type: COMPARATOR
Intervention: Taxus Liberté stents
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 323
Study: 20206924

Group type: EXPERIMENTAL
Intervention: Processing information in terms of its relevance to fitness-based scenarios in an ancestral environment (the grasslands)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Processing information in terms of its relevance to fitness-based scenarios in a modern urban environment (a city)
Number of subjects: 0
Study: 17955457

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) treatment
Number of subjects: 42
Study: 16840798

Group type: EXPERIMENTAL
Intervention: Pre-ovarian block (POB)
Number of subjects: 183
Study: 12722031

Group type: EXPERIMENTAL
Intervention: Low-dose prednisolone therapy (initial dose of 20 mg/d, tapered to 5 mg/d over 2 years)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (no steroid treatment)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Low-dose prednisolone therapy
Number of subjects: 90
Study: 11093446

Group type: EXPERIMENTAL
Intervention: Rofecoxib 12.5 mg once daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rofecoxib 25 mg once daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ibuprofen 800 mg 3 times daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Investigator assessment
Number of subjects: 0
Study: 8979658

Group type: EXPERIMENTAL
Intervention: Timolol maleate in solution (TS) 0.5 percent
Number of subjects: 28

Group type: COMPARATOR
Intervention: Timolol maleate in Gelrite (TXE) 0.5 percent
Number of subjects: 28
Study: 1461083

Group type: COMPARATOR
Intervention: MMSE scores above 25
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: MMSE scores between 18 and 24
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Correlation with MMSE scores
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Correlation with arterial blood pressure in high MMSE group
Number of subjects: 25
Study: 6393316

Group type: EXPERIMENTAL
Intervention: Cimetidine (800 mg daily intravenously for 2 days, then 1000 mg daily orally for 10 days in divided doses)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 55
Study: 28214596

Group type: EXPERIMENTAL
Intervention: certolizumab pegol (400 mg qd reduced to 200 mg qd after one month)
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: certolizumab pegol
Number of subjects: 382

Group type: COMPARATOR
Intervention: methotrexate
Number of subjects: 382
Study: 27235799

Group type: EXPERIMENTAL
Intervention: Acrolein and heptane mixture exposure
Number of subjects: 58

Group type: COMPARATOR
Intervention: Heptane only exposure
Number of subjects: 58
Study: 24823623

Group type: EXPERIMENTAL
Intervention: Zoster vaccine (ZV; Zostavax; Merck)
Number of subjects: 1000
Study: 22901348

Group type: EXPERIMENTAL
Intervention: Duloxetine (30 mg/d, increased to a maximum of 120 mg/d)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study: 20455766

Group type: EXPERIMENTAL
Intervention: efavirenz (EFV)
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: lopinavir/ritonavir (LPV/r)
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: atazanavir/ritonavir (ATV/r)
Number of subjects: 227
Study: 18541798

Group type: EXPERIMENTAL
Intervention: 75 g of sucrose 40 minutes before exercise
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 37 g of sucrose 5 minutes before exercise
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 16129987

Group type: EXPERIMENTAL
Intervention: Intrathecal isobaric bupivacaine (5-12 mg) with 10 microg fentanyl and 200 microg morphine
Number of subjects: 48

Group type: COMPARATOR
Intervention: Intrathecal isobaric bupivacaine (low doses 5-9 mg)
Number of subjects: 48
Study: 12033094

Group type: EXPERIMENTAL
Intervention: Nitrous oxide (50% N2O + 50% O2)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Lidocaine (mixed with propofol)
Number of subjects: 48
Study: 10449123

Group type: EXPERIMENTAL
Intervention: Pergolide monotherapy
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study: 7799707

Group type: EXPERIMENTAL
Intervention: Laparoscopic hysterectomy (LH)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Vaginal hysterectomy (VH)
Number of subjects: 98
Study: 2186237

Group type: EXPERIMENTAL
Intervention: Intravenous corticosteroids
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral corticosteroids (30 mg of prednisone or greater)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0